Regnum Corp.
Built from real-time financials, refreshed daily. For a full Analyst Grade with bull/bear case, price targets, and qualitative risk analysis, generate a RGMP research report →
About the company
Regnum Corp. is dedicated to advancing and marketing therapeutic agents designed to combat both rare and infectious diseases. Its flagship product is Leronlimab (PRO 140), a monoclonal antibody functioning as a C-C chemokine receptor type 5 (CCR5) antagonist.
- CEO
- Robert J. Stubblefield
- IPO
- 2019
- Employees
- 1
- HQ
- New York City, NY, US
Price Chart
- Market Cap
- $2.29K
- P/E
- -0.00
- P/S
- 0.00
- P/B
- -0.00
- EV/EBITDA
- -17.22
- Div Yield
- 0.00%
- Gross Margin
- 0.00%
- Op Margin
- 0.00%
- Net Margin
- 0.00%
- ROE
- 101.39%
- ROIC
- -186.44%
- Revenue
- $0 · 0.00%
- Net Income
- $-781,000 · -189.26%
- EPS
- $-0.03 · -193.10%
- Op Income
- $-736,000
- FCF YoY
- -5992.28%
- 52W High
- $0.00
- 52W Low
- $0.00
- 50D MA
- $0.00
- 200D MA
- $0.00
- Beta
- -0.82
- Avg Volume
- 386.4
Get TickerSpark's AI analysis on RGMP
Create an account to generate AI analysis on any ticker — technical setup, analyst consensus, earnings watch, insider pulse, financial health, and peer context. Ready in about a minute.
Get Pro Access →Already have an account? Log in
Our RGMP coverage
Recent articles, reports, and earnings notes.
No research on RGMP yet
For a full analyst-grade research report — grades, price targets, financials, chart analysis — generate one on demand.
Generate RGMP report →Similar companies
Peers in the same neighborhood.